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InﬂammationBackground: Studies on humans have related the high consumption of fructose, especially in the form of sugar-
sweetened beverages, to obesity, fatty liver, and hypercholesterolemia, all risk factors for atherosclerosis, and
cardiovascular disease. We aimed to determine whether supplementation of liquid fructose (SLF), in either a
normal, healthy chow or a Western-style chow, promoted the appearance of atherosclerosis in a rodent model.
Methods: LDL receptor knockoutmicewere fed for twelveweekswith normal chow, normal chow plus ad libitum
15% fructose solution, Western chow, or Western chow plus ad libitum 15% fructose solution (W+ F). Food and
liquid intake and body weight were periodically monitored. At the end of the study, plasma and hepatic lipids,
liver histology and expression of genes related to lipid handling were analyzed and histological and
immunohistological analyses of atherosclerosis at the aortic origin was performed.
Results: Total calorie intake was signiﬁcantly increased in Western-fed vs normal chow-fed mice, but was not
modiﬁed by SLF. SLF signiﬁcantly increased body weight, visceral adiposity, plasma lipids and liver cholesterol
content in Western-fed mice, probably due to an increase in de novo lipid synthesis. Aortic atherosclerotic total
lesion areawas signiﬁcantly correlated to plasma lipids, being highest inW+Fmice. Further, SLF induced higher
immunostaining for macrophages and oxidized-LDL receptor, independently of lesion area and caloric burden.
Conclusions: SLF, without changing total calorie intake, increases atherosclerosis, visceral adipose tissue and
cholesterol burden in a background of overweight LDL receptor knockout mice consuming an unhealthy,
Western-type solid rodent chow.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ó Privada Catalana de Nutrició i
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A sedentary lifestyle and unhealthy dietary habits are fueling the ep-
idemic of metabolic diseases, such as type 2 diabetes and obesity, and
the associated cardiovascular diseases related to atherosclerosis [1].
One of the most prevalent dietary changes over recent decades has
been the increasing consumption of simple sugars, mainly in the form
of sweetened beverages, especially among low income populations all
over the world [2]. Together with glucose, fructose in the form of su-
crose or high fructose corn syrup (HFCS) is one of the main sweeteners
used in the production of sodas and baked foods. Numerous studies in
recent years have related the high consumption of fructose or simple
sugars to ectopic fat deposition [3], hypercholesterolemia [4], ande under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tose or simple sugars, especially in the form of sugar-sweetened bever-
ages, has also been related to cardiovascular disease andmortality [6,7,8].
Due to metabolic similarities, the rat is a good model for studying
changes induced by fructose consumption in humans [9]. Fructose sup-
plementation of rats' drinking water (10% weight/volume), provides a
pattern of fructose consumption similar to that of the upper quintile of
human populations consuming high quantities of sugar-sweetened
beverages [10]. In previous studies, the use of this model enabled us to
demonstrate that fructose, but not glucose, induces hypertriglyc-
eridemia and fatty liver by simultaneously increasing liver fatty acid
synthesis and reducing liver fatty acid oxidation [11,12]. Moreover, at
least in female Sprague–Dawley rats, metabolic changes are accompa-
nied by alterations in liver glucose handling, with a marked reduction
in insulin receptor substrate-2 and silent regulator of translation-1 ex-
pression and activity [13,14]. These fructose-induced metabolic alter-
ations observed in rat are well known risk factors for the development
of atherosclerosis and related cardiovascular diseases in humans.
Consequently, we studied the inﬂuence of liquid fructose ingestion
in atherogenesis. As rats are resistant to atherosclerosis, we studied
the effect of liquid fructose supplementation in a murine model of
dietary-induced atherosclerosis, LDL receptor-deﬁcient (LDLR−/−)
mice [15]. We used two different solid dietary substrates, a standard
“healthy” rodent chow and an “unhealthy”, Western-type rodent
chow rich in saturated fat, reﬁned carbohydrates and cholesterol.
Supplementation of liquid fructose in LDLR−/−mice fed a standard ro-
dent show induced a non signiﬁcant increase in plasma lipid and liver
cholesterol content, but failed to signiﬁcantly increase atherosclerosis.
However, liquid fructose supplementation signiﬁcantly increased
atherosclerosis and liver and plasma lipid content in LDLR−/− mice
fed Western-type diet, despite ingesting exactly the same amount of
calories as LDLR−/−mice on Western-type diet only.
2. Materials and methods
2.1. Animals and experimental design
Male LDL−/−mice (C57BL/6 N) were purchased from Charles River
(France) andmaintainedwithwater and food ad libitum at constant hu-
midity and temperature with a light/dark cycle of 12 h. After three
weeks of acclimatizing, animals were randomly separated into four
groups of 10 mice each which received: 1. control rodent diet without
supplementary sugar: control group (C); 2. control rodent diet supple-
mented with 15% weight/volume fructose in drinking water: fructose-
supplemented group (F); 3. Western-type diet without supplementary
sugar: Western group (W); 4. Western-type diet supplemented with
15% weight/volume fructose in drinking water: Western plus fructose
group (W + F). The composition of control (2018 Teklad Global 18%
protein, Harlan Laboratories) andWestern-type (D12079B Open Source
Diets, Research Diets, Inc.) diets is detailed in Table 1.
During a feeding period of 12 weeks, consumed food and beverage
were measured every two days and body weight once a week. At
the end of the study, animals were sacriﬁced under intraperitonealTable 1
Composition of experimental diets.





Insoluble ﬁber 14.7% 5%
Lipids 6.2%⁎ 21%⁎⁎
cholesterol 0% 0.21%
⁎ Mainly unsaturated fat.
⁎⁎ 20% saturated fat from milk plus 1% corn oil.ketamine (100 mg/kg)/xylazine (10 mg/Kg) anesthesia between 9
and 10 a.m. after being fasted for 2 h. All procedures were conducted
in accordance with the guidelines established by the University of
Barcelona's Bioethics Committee, as stated in Law 5/1995 (21st July)
from theGeneralitat de Catalunya. These guidelines follow theDirective
2010/63/EU of the European Parliament on the protection of animals
used for scientiﬁc purposes.
2.2. Sample preparation
Blood sampleswere obtained by intracardiac punction at the time of
death and collected in micro tubes containing anticoagulant as additive
(Sarstedt AG & Co, Nümbrecht, Germany). Plasmawas obtained by cen-
trifugation and stored at−80 °C until used. Liver tissuewas excised and
fractionated. 10–100 mg were immediately frozen in liquid N2 and
stored at−80 °C until used for total RNA extraction. Another portion
for hepatic histological analysis was obtained. An additional section of
liver tissue (100mg)was perfused and stored at−80 °C for quantifying
liver lipids content. The upper atrial portions of hearts, including
the aortic valve, were excised and used for histological analysis, as
described below.
2.3. Leptin and lipid analysis
Plasma leptin and lipid levels were determined at the end of treat-
ment. Plasma leptin levels were determined with the RL83K RIA kit
from Linco Research (St. Charles, MO). Plasma triglycerides levels
were measured by Accutrend® Plus System glucometer (Cobas, Roche
Farma, Barcelona, Spain) using a speciﬁc test strips. Plasma cholesterol
was determined by Cholesterol CHOD-POD colorimetric test from
Spinreact (Girona, Spain).
Liver lipids were extracted according to Bligh & Dyer [16] method
using the homogenate fraction. The lipid extract was evaporated
under a stream of nitrogen gas and dissolved in absolute ethanol. Tri-
glycerides, total and free cholesterol contents in liver were determined
by using colorimetric tests: Triglycerides-LQ n° 41,030, Cholesterol
CHOD-POD n° 1,001,091 and Free-Cholesterol-LQ n° 41,035 from
Spinreact (Girona, Spain), respectively.
Size fractionation of plasma lipoproteins was performed by fast
performance liquid chromatography (FPLC) of pooled ﬁltered plasma
samples using a Superose 6® column as previously described [17]. In
each fraction, total cholesterol and triglyceride content was assayed.
2.4. RNA isolation and quantitative real-time PCR
Total RNA was isolated from 60 mg of liver tissue using TrizolR
reagent (Invitrogen™, Thermo-Fisher Scientiﬁc Inc., MA, USA), in accor-
dance with the manufacturer's guidelines. Single stranded cDNA was
synthesized by mixing 1 μg of liver total RNA, 125 ng of random
hexamers (Roche Farma, SA, Madrid, Spain,) as primers in the presence
of 5× First-Strand Buffer, 10 mM dithiothreitol (DTT), 200 units of
Moloney murine leukemia virus reverse transcriptase (M-MLV RT), 20
units of RNase OUT from Invitrogen™ and 0.5 mM of each dNTP
(Sigma-Aldrich, St. Louis, MO, USA) in a total volume of 20 μl. Samples
were incubated at 37°C for 60min inMJMini™ Personal Thermal Cycler
(Bio-Rad, Hércules, CA, USA).
The PCR reaction was carried out in StepOnePlus™ Real-Time PCR
System Thermal Cycling Block (Applied Biosystem, Foster City, CA,
USA). 20 μL of reaction mixture contained: Power SYBR® Green PCR
Master Mix (Applied Byosystems), 100 nM of each speciﬁc primer
(including forward and reverse primers) and 10 ng of cDNA for each
gene. After an initial denaturation at 95°C for 10min, 40 cycles of ampli-
ﬁcation were done. PCR reactions were performed in duplicate and
normalized to a housekeeping gene, the TATA box binding protein
(tbp) gene, using the 2−ΔΔCt method. The GenBank™ number, primer
sequences and PCR product length are listed in Supplemental Table 1.
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Total RNA, including small RNAs, was isolated using the miRNeasy
minikit in accordance with the manufacturer's protocol. For miRNA
quantiﬁcation, miRNAs were reverse-transcribed using miScript II
reverse transcription kit. Speciﬁc primers for each miRNA were used
and real time PCR was performed using the miScript SYBR Green PCR
kit on a 7900 HT Fast Real-Time PCR System (Applied Biosystems). All
reagents and kits used were from Qiagen (Las Matas, Madrid, Spain).
Relative expression of miRNAswas calculated by the 2−ΔΔCt method
using RNU6 for normalization. Only validated miRNAs for the target
genes were analyzed. Selection of validated miRNAs was assessed
using the MirWalk 3 [18] and miRTarbase 4 [19] databases.
2.6. Histological analysis
For hepatic histological analysis of Oil-Red O stained sections, the
liver tissue was perfused and ﬁxed in 10% paraformaldehyde solution
before processing for parafﬁn embedding. Images were acquired with
an Olympus BX71 microscope equipped with a DP72 camera and ana-
lyzed by a registered pathologist at BioBanc (Banc de tumors–IDIBAPS,
Barcelona Spain), who was unaware of the treatment groups. The area
of positive staining for Oil-Red O was calculated as a percentage of
stained cells/total section area in each sample.
For heart histological analysis, the upper portion of the heart was
excised, and placed in cryomolds (Cryomold Biopsy — Tissue Tek from
Sakura Finetek Europe B.V., Netherlands) preserved in Tissue-Tek
O.T.C. embedding medium, followed by freezing in dry ice-cooled
isopentane. Eightmicrometer serial sections of heart segments obtained
in a cryostat (Leyca® CM-1900) at−24 °C, were prepared and stained
with Oil-Red O and Hematoxilin-Eosin stain for histological evaluation
of cardiac structures. Lesion area was quantiﬁed following the standard
procedure by using Image-J software.
2.7. Immunohistochemistry studies
The immunohistochemistry analysiswas performed basically as pre-
viously described by Zhang and Ramos [20]. Serial frozen sections
of heart were examined for macrophage inﬁltration, inﬂammation and
oxidative stress using immunohistochemistry stain with several mono-
clonal antibodies: F4/80 (Santa Cruz Biotechnology Inc. Heidelberg,
Germany; reference product: sc-377,009), LOX1, p-NFκB-P65, RAGE
(AbCam, Bristol, UK; reference product: Ab60178, Ab131109, Ab3611,
respectively) and Anti-rabbit Alexa Fluor 594 (reference: A11012 from
Invitrogen, Life Technologies) used as a secondary antibody.
The slides were thawed at room temperature for 2 h, and ﬁxed with
acetone for 10min. After 30min of treatmentwith the blocking solution
(1% gelatin in PBS solution), tissue sections were incubated at room
temperature with primary antibody (dilution 1:1000) for 1 h. Slides
were washed with PBS twice and incubated with antirabbit Alexaﬂuor
594 secondary antibody for 1 h. After two washes with PBS, 20 μl of
Fluoromount-G (e-Bioscience, San Diego, CA, USA) were added to the
slides and covered. The images of the tissue sections were recorded
using a ﬂuorescencemicroscope and their color intensity wasmeasured
by Photoshop (Adobe Photoshop 7.0 software).
2.8. Statistical methods
Results are expressed as the mean of n values ± standard deviation.
Plasma and lipid samples were assayed in duplicate. Signiﬁcant differ-
ences between values from control, fructose and western groups were
established by the one-way ANOVA test and Bonferroni post-test for
selected comparisons; signiﬁcant differences between values from
western and western + fructose group were established by the un-
paired t-test (GraphPad Software V5). When the number of samples
was too small or variance was not homogeneous, a non-parametrictest was performed. The level of statistical signiﬁcance was set at
P ≤ 0.05.
3. Results
3.1. Liquid fructose supplementation in solid diet increases plasma lipids in
LDLR−/−mice
Zoometric parameters and plasma cholesterol, triglyceride and
leptin concentrations are shown in Table 2. LDLR−/− mice fed a solid
Western-type diet showed an increased body weight during and at
the end of treatment (×1.11 and ×1.24 fold, respectively, vs Control
(C) group). Although both the C andWestern (W) groups of mice con-
sumed equal amounts of solid diet, the high energy density of theWest-
ern diet yielded a ×1.49 fold increase in the amount of energy
consumed byWmice. Furthermore, Wmice showed increased concen-
trations of plasma cholesterol (×2.62 fold), triglyceride (×2.92 fold)
and leptin (×3.56 fold) vs C animals. Liquid fructose supplementation
in standard (F) or western (W + F) solid diet-fed animals increased
concentration of plasma cholesterol (×1.41 and ×1.73 fold vs C and W
groups, respectively) and triglyceride (×1.31 and ×1.39 fold vs C and
W groups, respectively), although only W+ F samples achieved statis-
tical signiﬁcance. Fast protein liquid chromatography (FPLC) analysis
(Fig. 1) indicated that triglycerides were transported in triglyceride-
rich lipoproteins (chylomicrons and VLDL), while cholesterol shifted
progressively from HDL and LDL (C samples) to triglyceride-rich lipo-
proteins (W and W + F samples). W + F mice showed an increased
body weight during and at the time of sacriﬁce (×1.11 and 1.19 fold
vsW, respectively), mainly due to an increased percentage of visceral
fat (×2.03 fold vs W). These fructose-induced changes in W + F mice
were apparent without signiﬁcant changes in the total amount of
energy consumed, due to a compensatory reduction in the amount of
ingested solid food (×0.83 fold vsW), together with a reduction in the
ingested volume of fructose solution (×0.77 fold vsW).
3.2. Liquid fructose supplementation in LDLR−/− mice alters hepatic
cholesterol homeostasis independently of the type of solid diet consumed
Histological analysis of Oil-Red O (ORO) liver sections showed no
differences among the different dietary groups in the percentage of
steatotic liver cells, which was always higher than 85–90% (Fig. 2A).
Only livers from the W + F group had micro- and macrovesicular
steatosis in all samples studied. Accordingly, liver triglyceride content
was unchanged in F andW groups with respect to C values, while livers
fromW+ F animals showed a ×1.55 fold increase in triglyceride con-
tent vsWanimals (Fig. 2B). In contrast, therewas a progressive increase
of total cholesterol content in liver among all dietary interventions
(×1.22 and ×2.54 fold vs C for F and W groups respectively), which
was further increased by the addition of fructose to the Western diet
(×1.72 fold W + F vs W). This change was mainly observed in the
cholesteryl-ester fraction, which was almost absent in the control
group and followed a similar pattern to that of total cholesterol (Fig. 2B).
We analyzed the liver expression of genes related to fatty acid and
cholesterol synthesis and metabolism (Fig. 2C). The Western diet did
not change the mRNA levels of genes related to fatty acid synthesis
(fatty acid synthase fas, stearoyl-CoA desaturase 1 scd1, and liver pyru-
vate kinase l-pk), with respect to control animals, but it did increase the
mRNA levels of genes related to fatty acid oxidation (liver carnitine
palmitoyltransferase 1 lcpt-1 and peroxisome proliferator activated
receptor α pparα), as well as reducing those related to cholesterol
synthesis (hydroxymethylglutaryl-Coenzyme A reductase hmgcrd),
and increasing the expression of genes related to lipoprotein uptake
(scavenger receptor-class B1 sr-b1, low density receptor related protein
1 lrp1, scavenger receptor-class A1 sr-a1, and cluster of differentiation
36 cd36). Fructose supplementation in both control and western diets
had the opposite effect, increasing liver mRNA levels of fatty acid and
Table 2
Zoometric parameters and plasma analytes of LDLR−/−mice exposed to four different dietary regimes for 84 days.
Parameters C F W W+ F
Final body weight (g) 26.6 ± 2.4 26.5 ± 4.9 33.0 ± 5.8## 39.2 ± 2.7⁎
Liver weight (g) 1.38 ± 0.31 1.37 ± 0.19 1.60 ± 0.27 2.35 ± 0.85⁎⁎
% Liver/body weight 4.9 ± 0.4 5.3 ± 0.9 4.9 ± 0.6 6.1 ± 1.2
VAT weight (g) 0.88 ± 0.38 1.08 ± 0.36 1.60 ± 1.02 3.25 ± 0.39⁎⁎
% VAT/body weight 3.1 ± 1.1 3.7 ± 1.0 4.2 ± 2.3 8.0 ± 0.6⁎
AUC weight (g/[animal × 84 days]) 161 ± 12 160 ± 17 179 ± 21# 199 ± 16⁎
AUC solid food intake (g/[animal × 84 days])a 271 ± 4 180 ± 18ᵻ 266 ± 37 221 ± 1
AUC liquid intake (ml/[animal × 84 days])a 448 ± 26 646 ± 60ᵻ 477 ± 6 369 ± 12⁎
Ingested solid kcal (animal × 84 days)a 840 ± 13 558 ± 56 1252 ± 176# 1041 ± 3
Ingested liquid kcal (animal × 84 days)a 0 388 ± 36 0 221 ± 7
Total ingested kcal (animal × 84 days)a 840 ± 13 946 ± 20 1252 ± 176# 1262 ± 11
Plasma cholesterol (mg/dL) 291 ± 14 410 ± 98 772 ± 272## 1337 ± 312⁎
Plasma triglycerides (mg/dL) 116 ± 16 151 ± 30 339 ± 146## 473 ± 86&
Plasma leptin (ng/mL) 4.8 ± 2.4 5.5 ± 2.9 17.1 ± 5.0## 20.5 ± 3.3
C: Standard solid-chow; F: Standard solid-chow plus a 15% fructose solution ad libitum; W:Western solid-chow;W+ F:Western solid-chow plus a 15% fructose solution ad libitum; VAT:
Visceral Adipose Tissue; AUC: Area Under the Curve. Values are expressed asmean± SDof 5–10 animals, except for Parameters, whichwere obtained from two cages containing at least 4
animals each.
a Parameters which were obtained from two cages containing at least 4 animals each.
# P b 0.05 vs C.
## P b 0.01 vs C.
& P= 0.09 – marginally signiﬁcant – vsW.
⁎ P b 0.05 vsW.
⁎⁎ P b 0.01 vsW.
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mRNA levels of fatty acid oxidation and lipoprotein uptake genes, with
the exception of the cd36 gene, in which mRNA levels were increased
by fructose supplementation, especially in the W + F group (×3.09
fold vsW). The mRNA level of peroxisome proliferator activated recep-
tor γ (PPARγ), a nuclear receptor involved in the control of CD36 [21],
was also signiﬁcantly increased in livers ofW+F rats (×2.95 fold vsW).
Toﬁnd a possiblemechanismwhich explained the increased expres-
sion of the hmgcrd gene by fructose, we assessed the expression of sev-
eral micro-RNAs that have been reported to control cholesterol
synthesis [22] (Fig. 3). We only detected a clear signiﬁcant increase in
the expression of miR-185-5p and miR-342-5p in the groups of mice
receiving a Western-type solid diet. Fructose supplementation in
Western diet decreased the expression of miR-122-3p.
3.3. Liquid fructose supplementation in LDLR−/− mice promotes
macrophage inﬁltration in aortic atherosclerosis plaques independently of
lipid deposition
To assess the extent of atherosclerosis we determined the lesion
percent area in ﬁve sequential cross-sections through the heart and aor-
tic origin; quantiﬁcation of the lesion percent area showed a signiﬁcant
increase in W samples from sections 1 to 5, while Fructose supplemen-
tation signiﬁcantly increased lesion percent area in sections 4 and 5Fig. 1.Percent distribution of total cholesterol (A) and triglycerides (B) among thedifferent FPLC
fed standard solid-chowplus a 15% fructose solution ad libitum),W (mice fedWestern solid-cho
fraction was analyzed in duplicate.fromW+ F animals versusW (Fig. 4A). For each of the dietary groups,
representative ORO-Hematoxylin-Eosin images of Section 3, corre-
sponding to the aortic valve leaﬂets, are shown in Fig. 4B; Section 3
was chosen because lesionswere visible beneath all three valve leaﬂets.
Quantiﬁcation of the total lesion area as AUCof lesion areas from section
1 to 5, as shown in Fig. 4C, demonstrated a signiﬁcant increase in W
group (×8.1 fold vs C), that was further increased in W + F (×2.6 vs
W). Total lesion area closely followed the progressive increase in
plasma lipids from F through W and W + F mice, presenting a direct
and signiﬁcant correlation with total plasma cholesterol (r2 = 0.824,
P b 0.0001) and triglycerides (r2 = 0.697, P b 0.0001) (Fig. 4D). Never-
theless, the increased atheromatous lesion did not result in stimulation
of nuclear factor kappa B (NFκB) mediated inﬂammation in the
vessel wall, as immunodetection of phospho-p65, a marker of NFκB ac-
tivation, indicated that this parameter was not modiﬁed in samples
from aortic sections 1 to 5 obtained from the different dietary groups
(Fig. 5A).
Again using immunohistochemistry, we detected the presence of
macrophages in the lesion area. Macrophage inﬁltration, detected by
speciﬁc F4/80 immunohistochemistry (Fig. 5B), did not follow the pat-
tern of increased lesion area, being signiﬁcantly increased practically
in all the aortic sections studied from F group; theW+ F group showed
a similar pattern, but due to high sample variability statistical signiﬁ-
cance vs W group was only achieved in section 4. A similar behaviorfractions of pooledﬁlteredplasma samples fromC (mice fed standard solid-chow), F (mice
w), andW+F (mice fedWestern solid-chow plus a 15% fructose solution ad libitum). Each
Fig. 2. A. Histological study of liver sections from Control C (mice fed standard solid-chow), Fructose F (mice fed standard solid-chow plus a 15% fructose solution ad libitum), WesternW
(mice fedWestern solid-chow), andWestern + Fructose W+ F (mice fedWestern solid-chow plus a 15% fructose solution ad libitum). Livers were cryosectioned and processed for his-
tological examination of fat inﬁltration by Oil-Red O staining. A representative image of liver sections from each experimental group is shown. B. Bar plots showing the liver content of
different lipid species from the four experimental dietary groups of mice (mean ± sd of ﬁve different liver samples). C. Bar plots showing the relative levels of speciﬁc mRNAs from
the four experimental dietary groups of mice (mean ± sd of ﬁve different liver samples). #P b 0.05, ##P b 0.01 vs C values; *P b 0.05, **P b 0.01 vsW values.
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tor 1 (LOX1) (Fig. 6A). In the case of another modiﬁed receptor studied,
the receptor for advanced glycation end products (RAGE), the high dis-
persion of the immunohistochemical data precluded the validation of
any signiﬁcant change (Fig. 6B).4. Discussion
A signiﬁcant relationship between higher sugar consumption and
increased risk for cardiovascular disease (CVD) mortality has been
found in humans, and the association remains signiﬁcant after adjusting
Fig. 3. Bar plots showing the relative levels of speciﬁc miRNAs, as mean ± sd, in four dif-
ferent liver samples obtained from C (mice fed standard solid-chow), F (mice fed standard
solid-chowplus a 15% fructose solution ad libitum),W (mice fedWestern solid-chow), and
W+ F (mice fed Western solid-chow plus a 15% fructose solution ad libitum). #P b 0.05,
##P b 0.01 vs C values; *P b 0.05 vsW values.
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marker of unhealthy dietary habits, the association is not explained by
overall diet quality, and it is also consistently observed in the speciﬁc
case of sugar-sweetened beverage consumption [8]. As previously re-
ported byMalik et al. [23], one of the proposed causes of this association
is fructose, found in similar amounts in sucrose and HFCS. Thus,
epidemiological studies indicate that added fructose may increase
blood pressure and blood pressure variability, enhance heart rate and
myocardial oxygen demand, and contribute to insulin resistance and
general metabolic dysfunction in humans (for detailed information
see reviews [24,25]). In the present study, we found that at an identical
calorie consumption, fructose supplementation in liquid form, besides
increasing body weight and visceral adiposity, promoted atherosclero-
sis in LDL receptor (LDLR)−/− mice fed an unhealthy, Western-type
solid chow. This latter effect was directly related to the increase in
plasma lipid levels induced by fructose supplementation. Moreover,
the addition of liquid fructose to a solid diet signiﬁcantly increased the
expression of amacrophagemarker and amodiﬁed lipoprotein receptorin atherosclerotic plaques, independently of the extension of the lesion
area and the type of solid diet consumed.
Among the experimental models available for the study of athero-
sclerosis, non-human primates and rabbits develop atherosclerosis
lesions that are more or less similar to those in humans in response to
a cholesterol-enriched diet [26]. Besides ethical concerns, non-human
primates are both expensive and difﬁcult to house and handle, while
rabbits present a disproportionate response to dietary cholesterol.
There are few published reports about the effect of fructose supplemen-
tation on the development of atherosclerosis in these species. Suzuki
et al. [27,28] reported an accumulation of aortic foam cells and inﬁltrat-
ed macrophages after feeding cynomolgus monkeys with a solid diet
containing 1% cholesterol and a high proportion of fructose (31%).
Akira et al. [29] detected an increase in aortic intimal thickening after
feeding a solid diet (1% cholesterol) supplemented with liquid fructose
(10% w/v) to rabbits for 8 weeks. Unfortunately, the effect of the
cholesterol-rich solid diet alone was not reported in either case.
Genetically modiﬁed rodents are a valid alternative for the study of
atherosclerosis [30]. In the two most used models, Apo E−/− and
LDLR−/− mice, the former develops spontaneous aortic lesions when
fed normal chow, while the latter develops atherosclerosis only when
fed a Western-type diet, reproducing the pattern of dietary effects ob-
served in humans. Cannizzo et al. [31] demonstrated enlarged athero-
sclerotic lesions in aortic and carotid arteries after feeding Apo E−/−
mice on normal chow supplemented with liquid fructose (10% w/v)
for 8weeks.Merat et al. [32] reported an increase in atherosclerosis bur-
den after feeding the more diet-sensitive model, the LDLR−/−mouse,
for 5.5 months on a fructose-enriched diet that provided a very
unphysiological proportion of energy (61%) from fructose.
To ascertain if the effect of liquid-fructose supplementation on
atherosclerosis was different depending on the type of basal dietary
substrate, we fed LDLR−/−mice on two different solid diets, a normal,
“healthy” mouse chow, and an “unhealthy” mouse diet Western-style,
enriched in saturated fat, simple carbohydrates and cholesterol, supple-
mented or not with a solution of fructose 15% weight/volume. Mice
were fed on these diets for twelve weeks, a period sufﬁcient to induce
detectable atherosclerosis [15].
4.1. Impact of fructose supplementation on lipid-related parameters
After this feeding period, fructose supplemented mice had con-
sumed an amount of calories from liquid-fructose in the range of the
upper quintiles of human consumption (17 and 41% of total energy in
W + F and F group, respectively). Nonetheless, the amount of total
consumed calories was not signiﬁcantly increased in both fructose-
supplemented groups versus their corresponding controls. This ﬁnding
enabled us to discriminate fructose-derived effects from those driven
by a huge increase in the total intake of ingested calories, as in the
case between C and W animals (1252 vs 840 kcal for W and C, respec-
tively). Of note, while mice on Western diet signiﬁcantly weighted
more than controls (×1.24 fold) at the end of the study, as could be ex-
pected from the increase in the total amount of calories ingested (×1.49
fold vs C), fructose-supplementation in Western-type fed mice also sig-
niﬁcantly increased bodyweight (×1.19 fold vsW), despite both groups
of mice consuming identical amount of calories. It must be pointed out
that animals adjusted their calorie intake through the length of the
study spontaneously. Leptin is a key adipocytokine controlling long
term energy intake, whose plasma values are directly related to body
weight [33]. Plasma leptin concentration and body weight were un-
changed after fructose supplementation in LDL receptor (LDLR)−/−
mice fed control chow, while they were increased in Western-type fed
vs control mice. Further, although the difference in plasma leptin
between W + F vs W values did not reach statistical signiﬁcance, it
increased exactly in the same proportion as the change in ﬁnal body
weight between both groups of animals (×1.2 fold W + F vs W, see
Table 2). Thus, it can be assumed that, at least under the same solid
Fig. 4.A. Representative plot showing lesion percent area (mean± sd of 3–5 different heart samples) in ﬁve sequential cross-sections through the heart and aortic origin stainedwith Oil-
Red O andHematoxylin-Eosin of samples obtained from C (mice fed standard solid-chow), F (mice fed standard solid-chow plus a 15% fructose solution ad libitum), W (mice fedWestern
solid-chow), andW+ F (mice fedWestern solid-chow plus a 15% fructose solution ad libitum). The table below Fig. 4A shows the statistical signiﬁcance for each comparison. For each of
the dietary groups studied, representative images corresponding to the aortic valve leaﬂets (Section 3), are shown (B). C. Bar plot showing the total lesion area (mean± sd of 4–5mice) of
the AUC from section 1 to 5 from the four experimental dietary groups of mice. D. Correlation plots between total lesion area and either total cholesterol or triglyceride concentrations in
plasma samples from the four dietary groups of mice studied. ##P b 0.01 vs C values; **P b 0.01 vsW values.
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leptin was preserved after fructose supplementation, thus helping to
maintain the total amount of ingested calories to similar values.
Besides the well-known hypertriglyceridemic effect, there was also
an increase in plasma cholesterol in the fructose-supplemented animals
that reached signiﬁcance in theW+ F group. Although this latter effect
could depend on the experimental animal used (LDL-R−/−mice devel-
op hypercholesterolemia under fructose-supplementation (32); rats
normally do not), a recent meta-analysis of controlled feeding trials in
humans has shown that a high fructose intake increases plasma LDL-
cholesterol and total cholesterol concentrations [4]. The increase in
plasma cholesterol could not be attributed to a dietary origin, given
that the amount of solid chow ingested was similar (W + F vs W) or
even signiﬁcantly reduced (F vs C) among the dietary groups studied
[34]. Our results showing increased liver levels of the speciﬁc mRNA
for HMGCRD in samples from fructose-supplemented mice, suggests a
fructose-driven increase in the endogenous synthesis of cholesterol.
This effect can be ascribed to fructose itself, rather than to the increased
caloric burden provided by the sugar, as total caloric intake was not
different among the “healthy” and “Western” dietary groups, indepen-
dently of fructose supplementation (see Table 2). The presence ofdietary cholesterol in theWestern diet could explain themarked reduc-
tion in the expression of HMGCRD observed inW andW+ Fmice. This
ﬁnding was in agreement with the increased levels of miRNAs, such as
miR-342-5p and especially miR-185-5p in the same groups of mice;
the increased expression of these miRs has been related to reductions
in liver cholesterol synthesis [22] [35]. The progressive reduction in
the expression of miR-122-3p, signiﬁcant inW+ F vsWmice, in paral-
lel with lipid deposition in liver (see Fig. 2B), would be in agreement
with the reported reduction in miR-122 in nonalcoholic fatty liver
disease (NAFLD) patients [36]. Unfortunately, none of the changes
detected in the studied miRNAs could explain the effect of fructose
supplementation on the expression of the hmgcrd gene.
The increase in liver fatty acids being incorporated into triglycerides,
due to endogenous synthesis (F), diet (W), or both origins (W+ F)was
probably the main factor responsible for the increase in liver CD36 ex-
pression. CD36 in the plasma membrane of hepatocytes facilitates the
incorporation of fatty acids and native and modiﬁed lipoproteins into
liver metabolism [21], and increased liver expression of CD36 has
been detected in experimental models of NAFLD and in NAFLD patients
[37]. PPARγ, the expression and activity ofwhich has been related to the
development of hepatic steatosis [38], controls the expression of CD36.
Fig. 5. Representative images of Section 3, corresponding to the aortic valve leaﬂets, by speciﬁc immunohistochemistry for p65 (A) and F4/80 (B) obtained fromC (mice fed standard solid-
chow), F (mice fed standard solid-chow plus a 15% fructose solution ad libitum),W (mice fedWestern solid-chow), andW+ F (mice fedWestern solid-chow plus a 15% fructose solution
ad libitum). The bar plot on the right-hand of the images shows relative color intensity, as mean ± sd, in 3–5 different images of Section 1 to 4 (F4/80)/5 (p65) obtained from the four
experimental dietary groups of mice. ##P b 0.01 vs C values; **P b 0.01 vsW values.
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mulation of lipids in liver, especially in the W + F group, could be
responsible for the increased expression of PPARγ and its target gene
cd36. Based on our data, we cannot rule out the possibility that some
of the increase in liver cholesterol concentration could be due to the in-
corporation of plasma lipoproteins by CD36 binding and internalization.
To summarize, fructose supplementation in liquid form in a back-
ground of overweight mice consuming an unhealthy, Western-type
solid rodent chow, worsened themetabolic phenotype (visceral obesity
and dyslipidemia) of these animals even without increasing their total
calorie intake, pointing to a speciﬁc, deleterious effect of fructose
metabolism. These results are in accordance with recent clinical data
showing higher sensibility of already obese subjects to the obesogenic
effects of fructose [40].
4.2. Impact of fructose supplementation on atherosclerosis
Lipid deposition and local inﬂammation in the vessel wall, driven by
inﬁltrated monocyte/macrophages, are accepted causes of atheroma
formation [41]. Both factors were markedly altered by fructose supple-
mentation in LDLR−/− mice. As expected, given that plasma lipids –
especially cholesterol – are the main recognized risk factors for athero-
sclerosis [42], there was a direct correlation between plasma lipids and
total atherosclerotic lesion area across the four different dietary groups
studied. Fructose supplementation signiﬁcantly increased plasma lipids
and total lesion area in mice fed Western-type solid diet and, more im-
portant, independently of the total amount of energy consumed. Thus,
despite W + F and W mice had exactly the same caloric intake,
W+F animals showed increases in plasma cholesterol (×1.73 fold), tri-
glycerides (×1.39 fold) and total lesion area (×2.65 fold)with respect to
W values. Thus, fructose had a deleterious effect on atheromatousplaque formation that is due to its particular metabolism; substituting
calories provided by the solid Western-diet (221 kcal, see Table 2)
with the same amount of calories provided by liquid fructose clearly
worsened dyslipidemia and aortic lesion.
The recruitment of blood monocytes to the vessel wall and their
transformation into lipid-laden macrophages forming early fatty-
streaks constitutes the initial building block of atherosclerosis. Oxida-
tive modiﬁcation of lipids trapped in the vessel wall is the driving
force behind macrophage-lipid engulfment and foam-cell formation
[41]. Despite the progressive increase in arterial wall lesion area across
the four dietary groups, only the two fructose-supplemented groups
showed signiﬁcant increases in macrophage inﬁltration, as determined by
F4/F80 immunostaining. Macrophage detection paralleled immunodetection
of a modiﬁed lipid receptor, LOX-1, that is present on the surface of cells in-
volved in the formation of atherosclerosis plaque, including macrophages,
and is responsible for the selective uptake of oxidized-LDL [43]. This effect
of fructose was also independent of the type of solid food consumed
(either standard or Western-type) and of the total energy intake, once
again conﬁrming a speciﬁc effect of the fructose molecule on plaque forma-
tion thatwas unrelated to the caloric burdenprovided by its ingestion.More-
over, in this case, fructose supplementation sufﬁced to induce similar
increases in macrophage recruitment and selective LOX-1 detection,
irrespective of the lesion area (compare Figs. 4C, 5B, and6A). The selective in-
crease in F4/F80 and LOX-1 immunostaining in F andW+Fgroups could be
attributed to a speciﬁc effect of fructose enhancing thedepositionofmodiﬁed
lipoproteins in the vessel wall, whichwould recruitmonocytes through local
inﬂammation and chemoattractant cytokine production [41]. However, we
did not detect changes in the immunostaining of phospho-p65, a marker of
NFkB activation. NFkB is a pro-inﬂammatory transcription factor involved in
the promotion of inﬂammation within the arterial wall and atheromatous
plaque [44]. The short feeding period (twelve weeks) chosen in our study
Fig. 6. Representative images of Section 3, corresponding to the aortic valve leaﬂets, by speciﬁc immunohistochemistry for LOX1 (A) and RAGE (B) obtained from C (mice fed standard
solid-chow), F (mice fed standard solid-chow plus a 15% fructose solution ad libitum), W (mice fed Western solid-chow), and W+ F (mice fed Western solid-chow plus a 15% fructose
solution ad libitum). The bar plot on the right hand of the images shows relative color intensity, asmean± sd, in 3–4 different images of Section 1 to 5 obtained from the four experimental
dietary groups of mice. #P b 0.05 vs C values; $P= 0.06 – marginally signiﬁcant – vs C; **P b 0.01 vsW values; &P= 0.09 – marginally signiﬁcant – vsW.
20 N. Hutter et al. / IJC Metabolic & Endocrine 9 (2015) 12–21to induceatherosclerosisplaque formation [15] could imply that therewasan
insufﬁcient build-up of the inﬂammatory process for it to be signiﬁcantly de-
tected by phospho-p65 immunostaining.4.3. Study limitations
We are well aware of the shortcomings of our experimental model,
as regards the direct extrapolation of data obtained from a genetically
modiﬁed mouse to humans, and the high amount of fructose ingested,
whichwas higher than the average consumption of fructose by humans.
Nevertheless, in our animal model fructose was supplemented for a
short period of time, while the patterns of human fructose consumption
could span many years.
In addition, although themolecularmechanism involved is not clear
at this point, our results indicate that fructose is not merely a “calorie
provider” in the human-food chain, but also introduces a deleterious
effect inherent to its particular metabolism that could accelerate the
development of atherosclerosis and cardiovascular disease, especially
in overweight people with unhealthy dietary habits.
In conclusion, our results show that fructose consumption in liquid
form increases body weight, atherosclerosis and cholesterol burden in
LDLR−/− mice independently of energy intake, and signiﬁcantly in
those animals consuming an “unhealthy” solid rodent diet, mimicking
a Western-type diet consumed by humans.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcme.2015.10.002.Acknowledgments
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